Literature DB >> 15293996

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.

Jing-Ping Liou1, Yi-Ling Chang, Fu-Ming Kuo, Chun-Wei Chang, Huan-Yi Tseng, Chiung-Chiu Wang, Yung-Ning Yang, Jang-Yang Chang, Shiow-Ju Lee, Hsing-Pang Hsieh.   

Abstract

The synthesis and study of the structure-activity relationships of two new classes of synthetic antitubulin compounds based on 1-aroylindole and 3-aroylindole skeletons are described. Lead compounds 3, 10, and 14 displayed potent cytotoxicities with IC50 = 0.9-26 nM against human NUGC3 stomach, MKN45 stomach, MESSA uterine, A549 lung, and MCF-7 breast carcinoma cell lines. The inhibition of proliferation correlated with in vitro polymerization inhibitory activities. Structure-activity relationships revealed that 6-methoxy substitution of 3-aroylindoles and 5-methoxy substitution of 1-aroylindoles contribute to a significant extent for maximal activity by mimicking the para substitution of the methoxy group to the carbonyl group in the case of aminobenzophenones. Addition of a methyl group at the C-2 position on the indole ring exerts an increased potency. The 3,4,5-trimethoxybenzoyl moiety was necessary for better activity but not essential and can be replaced by 3,5-dimethoxybenzoyl and 3,4,5-trimethoxybenzyl moieties. We conclude that 1- and 3-aroylindoles constitute an interesting new class of antitubulin agents with the potential to be clinically developed for cancer treatment. Copyright 2004 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293996     DOI: 10.1021/jm049802l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

Authors:  Matthew T Macdonough; Tracy E Strecker; Ernest Hamel; John J Hall; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2013-07-23       Impact factor: 3.641

2.  Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

Authors:  Mallinath B Hadimani; Matthew T Macdonough; Anjan Ghatak; Tracy E Strecker; Ramona Lopez; Madhavi Sriram; Benson L Nguyen; John J Hall; Raymond J Kessler; Anupama R Shirali; Li Liu; Charles M Garner; George R Pettit; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2013-09-09       Impact factor: 4.050

3.  Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.

Authors:  Mei-Jung Lai; Han-Li Huang; Shiow-Lin Pan; Yi-Min Liu; Chieh-Yu Peng; Hsueh-Yun Lee; Teng-Kuang Yeh; Po-Hsien Huang; Che-Ming Teng; Ching-Shih Chen; Hsun-Yueh Chuang; Jing-Ping Liou
Journal:  J Med Chem       Date:  2012-04-05       Impact factor: 7.446

4.  Highly potent triazole-based tubulin polymerization inhibitors.

Authors:  Qiang Zhang; Youyi Peng; Xin I Wang; Susan M Keenan; Sonia Arora; William J Welsh
Journal:  J Med Chem       Date:  2007-01-24       Impact factor: 7.446

5.  New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer.

Authors:  Giuseppe La Regina; Ruoli Bai; Antonio Coluccia; Valeria Famiglini; Sveva Pelliccia; Sara Passacantilli; Carmela Mazzoccoli; Vitalba Ruggieri; Annalisa Verrico; Andrea Miele; Ludovica Monti; Marianna Nalli; Romina Alfonsi; Lucia Di Marcotullio; Alberto Gulino; Biancamaria Ricci; Alessandra Soriani; Angela Santoni; Michele Caraglia; Stefania Porto; Eleonora Da Pozzo; Claudia Martini; Andrea Brancale; Luciana Marinelli; Ettore Novellino; Stefania Vultaggio; Mario Varasi; Ciro Mercurio; Chiara Bigogno; Giulio Dondio; Ernest Hamel; Patrizia Lavia; Romano Silvestri
Journal:  J Med Chem       Date:  2015-07-20       Impact factor: 7.446

6.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies.

Authors:  Giuseppe La Regina; Taradas Sarkar; Ruoli Bai; Michael C Edler; Roberto Saletti; Antonio Coluccia; Francesco Piscitelli; Lara Minelli; Valerio Gatti; Carmela Mazzoccoli; Vanessa Palermo; Cristina Mazzoni; Claudio Falcone; Anna Ivana Scovassi; Vincenzo Giansanti; Pietro Campiglia; Amalia Porta; Bruno Maresca; Ernest Hamel; Andrea Brancale; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity.

Authors:  Christopher J Trabbic; Sage M George; Evan M Alexander; Shengnan Du; Jennifer M Offenbacher; Emily J Crissman; Jean H Overmeyer; William A Maltese; Paul W Erhardt
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

8.  Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Po-Kai Huang; Hsu-Chin Chan; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Bioorg Med Chem       Date:  2013-06-26       Impact factor: 3.641

9.  How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site.

Authors:  Chenxiao Da; Susan L Mooberry; John T Gupton; Glen E Kellogg
Journal:  J Med Chem       Date:  2013-09-09       Impact factor: 7.446

10.  Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Authors:  Vinod Kumar Sanna; Manu Jaggi; Vadlapudi Kumar; Anand C Burman
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.